$ZVRA News
Last published 1w ago
- 1w agoZVRAZevra Therapeutics Third Quarter 2026 Results - ZEVRA THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and thank you for joining Zebra's third quarter 2026 financial results and corporate update conference call. Today's call is being recorded and will be available via the investor relations section of the
- 1w agoZVRAZEVRA THERAPEUTICS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoZVRAZevra Reports Third Quarter 2026 Financial Results and Corporate UpdateGlobeNewswire$37.8 million net revenue for Q3 2026, driven by $34.0 million in revenue from MIPLYFFA 45% increase in total net revenue over Q3 2025 Operational execution fueled strong cash position of $270.9 million Company to
- 3w agoZVRAZevra Therapeutics Announces Details for Q3 2026 Financial Results CallGlobeNewswireBOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases,
- 1mo agoZVRAMorgan Stanley 24th Annual Global Healthcare Conference - ZEVRA THERAPEUTICS INCEarnings Call TranscriptsAll right, great. Thank you all for coming to the Morgan Stanley Healthcare Conference. My name is Ruck Byun. I'm the head of West Coast Healthcare Investment Banking at Morgan Stanley. I have the pleasure of hosting the
- 1mo agoZVRAMorgan Stanley 24th Annual Global Healthcare Conference - ZEVRA THERAPEUTICS INCEarnings Call TranscriptsAll right, great. Thank you all for coming to the Morgan Stanley Healthcare Conference. My name is Ruck Byun. I'm the head of West Coast Healthcare Investment Banking at Morgan Stanley. I have the pleasure of hosting the
- 2mo agoZVRAZevra Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases,
- 2mo agoZVRAZevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual SymposiumGlobeNewswireBOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases,
- 2mo agoZVRAZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare
- 3mo agoZVRACG 46TH ANNUAL GROWTH CONFERENCE - ZEVRA THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. I'm Samanth Kulkarni, a senior biotechnology analyst here at Canaccord Genuity, and it's my pleasure to have Zevra Therapeutics with us here today. ZevrA, as you might know, has a product that's a
- 3mo agoZVRACG 46TH ANNUAL GROWTH CONFERENCE - ZEVRA THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. I'm Samanth Kulkarni, a senior biotechnology analyst here at Canaccord Genuity, and it's my pleasure to have Zevra Therapeutics with us here today. ZevrA, as you might know, has a product that's a
- 3mo agoZVRAZevra Therapeutics Second Quarter 2026 Results - ZEVRA THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and thank you for joining Zevra's second quarter 2026 financial results and corporate update conference call. Today's call is being recorded and will be available via the investor relations section of the
- 3mo agoZVRAZevra Reports Second Quarter 2026 Financial Results and Corporate UpdateGlobeNewswire$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 million Company to
- 3mo agoZVRAZevra Therapeutics to Present at the Canaccord Genuity Annual Growth ConferenceGlobeNewswireBOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases,
- 3mo agoZVRAZevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)GlobeNewswireBOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases,
- 3mo agoZVRAZevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European UnionGlobeNewswireCompany plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access Program BOSTON,
- 3mo agoZVRAZevra Therapeutics Announces Details for Q2 2026 Financial Results CallGlobeNewswireBOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare
- 4mo agoZVRAZevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)GlobeNewswireBOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases,
- 5mo agoZVRAZevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionGlobeNewswireBOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases,
- 5mo agoZVRAZevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFAGlobeNewswireMIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE
- 5mo agoZVRAZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases,
- 6mo agoZVRAZevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor ConferenceGlobeNewswireBOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced
- 6mo agoZVRAZevra Reports First Quarter 2026 Financial Results and Corporate UpdateGlobeNewswireQ1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to
- 6mo agoZVRAZevra Therapeutics Announces Details for Q1 2026 Financial Results CallGlobeNewswireBOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced
- 8mo agoZVRAZevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 MillionGlobeNewswireBOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced
- 8mo agoWGSZVRAGeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type CBusiness WireProgram to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the
- 8mo agoZVRAZevra Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireQ4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35
- 8mo agoZVRAZevra Therapeutics Appoints Justin Renz as Chief Financial OfficerGlobeNewswireCELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 8mo agoZVRAZevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results CallGlobeNewswireCELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 8mo agoZVRAZevra Therapeutics to Present at the Citizens Life Sciences ConferenceGlobeNewswireCELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 8mo agoZVRATranspire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial OfficerGlobeNewswireSUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today
- 9mo agoZVRAZevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™GlobeNewswireCELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 9mo agoZVRAZevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026GlobeNewswireCELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 9mo agoZVRAZevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™GlobeNewswireFour abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium on diagnostic and
- 10mo agoZVRAZevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare ConferenceGlobeNewswireCELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 10mo agoZVRAZevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)GlobeNewswireCELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 11mo agoZVRAZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 11mo agoZVRAZevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhDGlobeNewswireCELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 11mo agoZVRAZevra Therapeutics, Inc. Announces CFO TransitionGlobeNewswireCELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,
- 1y agoZVRAZevra Reports Third Quarter 2025 Financial Results and Corporate UpdateGlobeNewswire2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla.,
- 1y agoZVRAZevra Therapeutics to Participate in the Guggenheim Healthcare Innovation ConferenceGlobeNewswireCELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 1y agoZVRAZevra Therapeutics Announces Details for Q3 2025 Financial Results CallGlobeNewswireCELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 1y agoZVRAZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 1y agoZVRAZevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)GlobeNewswireMIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial
- 1y agoZVRAZevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)GlobeNewswireNew data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster
- 1y agoZVRAZevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)GlobeNewswireCELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 1y agoZVRAZevra Therapeutics to Participate at Upcoming Investor Conferences in SeptemberGlobeNewswireCELEBRATION, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today
- 1y agoZVRAZevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoZVRAZevra Reports Second Quarter 2025 Financial Results and Corporate UpdateGlobeNewswireQ2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and
- 1y agoZVRAZevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireCELEBRATION, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today